Cargando…
Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
SIMPLE SUMMARY: Fibroblast growth factor-23 (FGF-23) is used to monitor chronic kidney disease in humans. The value of FGF-23 in cats is largely unknown. The aim of this study was to compare three different FGF-23 diagnostic assays and to assess their correlation with renal function parameters in ca...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251965/ https://www.ncbi.nlm.nih.gov/pubmed/37889764 http://dx.doi.org/10.3390/ani13111853 |
_version_ | 1785056058031472640 |
---|---|
author | Lapsina, Sandra Nagler, Nicole Müller, Simon F. Holtdirk, Annette Kottmann, Tanja Müller, Elisabeth von Luckner, Jennifer Schäfer, Ingo |
author_facet | Lapsina, Sandra Nagler, Nicole Müller, Simon F. Holtdirk, Annette Kottmann, Tanja Müller, Elisabeth von Luckner, Jennifer Schäfer, Ingo |
author_sort | Lapsina, Sandra |
collection | PubMed |
description | SIMPLE SUMMARY: Fibroblast growth factor-23 (FGF-23) is used to monitor chronic kidney disease in humans. The value of FGF-23 in cats is largely unknown. The aim of this study was to compare three different FGF-23 diagnostic assays and to assess their correlation with renal function parameters in cats. Four groups were formed retrospectively on the basis of creatinine concentration classification according to the IRIS guidelines. Measurements were performed in 40 cats in total. The Kainos ELISA assay (FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan) showed the highest correlations for all study groups. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. ABSTRACT: Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone used to monitor chronic kidney disease (CKD) in humans. The aim of this pilot study was to compare three diagnostic assays and to assess how the results correlate with parameters of renal dysfunction in cats. Four groups of 10 cats each were formed retrospectively according to creatinine, based on IRIS staging. FGF-23 was measured using two different ELISAs (MyBioSource and Kainos ELISA FGF-23 Kit) and an automated assay on the DiaSorin Liaison platform. Measurements were performed in 40 cats. Spearman’s rank correlation coefficient showed a strong correlation between the Kainos and DiaSorin assays (ρ = 0.742/p < 0.001) and a low correlation (ρ = 0.443/p = 0.005) between the Kainos and MyBioSource assays. The measurements with the Kainos assay strongly correlated with urea (ρ = 0.835/p < 0.001) and creatinine (ρ = 0.764/p < 0.001), and moderately correlated with SDMA (ρ = 0.580/p < 0.001) and phosphorus (ρ = 0.532/p < 0.001). The results of the MyBioSource and DiaSorin assays only showed a moderate correlation with urea (ρ = 0.624/0.572) and creatinine (ρ = 0.622/0.510) concentrations (p = 0.001 each). The Kainos assay showed the strongest correlation (ρ = 0.806) with the various creatinine concentrations according to the IRIS, followed by the MyBioSource (ρ = 0.663/p < 0.001) and DiaSorin assays (ρ = 0.580/p < 0.001). Overall, the Kainos assay demonstrated the best correlations with both biomarkers and various creatinine concentrations according to the IRIS. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. |
format | Online Article Text |
id | pubmed-10251965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102519652023-06-10 Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study Lapsina, Sandra Nagler, Nicole Müller, Simon F. Holtdirk, Annette Kottmann, Tanja Müller, Elisabeth von Luckner, Jennifer Schäfer, Ingo Animals (Basel) Article SIMPLE SUMMARY: Fibroblast growth factor-23 (FGF-23) is used to monitor chronic kidney disease in humans. The value of FGF-23 in cats is largely unknown. The aim of this study was to compare three different FGF-23 diagnostic assays and to assess their correlation with renal function parameters in cats. Four groups were formed retrospectively on the basis of creatinine concentration classification according to the IRIS guidelines. Measurements were performed in 40 cats in total. The Kainos ELISA assay (FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan) showed the highest correlations for all study groups. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. ABSTRACT: Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone used to monitor chronic kidney disease (CKD) in humans. The aim of this pilot study was to compare three diagnostic assays and to assess how the results correlate with parameters of renal dysfunction in cats. Four groups of 10 cats each were formed retrospectively according to creatinine, based on IRIS staging. FGF-23 was measured using two different ELISAs (MyBioSource and Kainos ELISA FGF-23 Kit) and an automated assay on the DiaSorin Liaison platform. Measurements were performed in 40 cats. Spearman’s rank correlation coefficient showed a strong correlation between the Kainos and DiaSorin assays (ρ = 0.742/p < 0.001) and a low correlation (ρ = 0.443/p = 0.005) between the Kainos and MyBioSource assays. The measurements with the Kainos assay strongly correlated with urea (ρ = 0.835/p < 0.001) and creatinine (ρ = 0.764/p < 0.001), and moderately correlated with SDMA (ρ = 0.580/p < 0.001) and phosphorus (ρ = 0.532/p < 0.001). The results of the MyBioSource and DiaSorin assays only showed a moderate correlation with urea (ρ = 0.624/0.572) and creatinine (ρ = 0.622/0.510) concentrations (p = 0.001 each). The Kainos assay showed the strongest correlation (ρ = 0.806) with the various creatinine concentrations according to the IRIS, followed by the MyBioSource (ρ = 0.663/p < 0.001) and DiaSorin assays (ρ = 0.580/p < 0.001). Overall, the Kainos assay demonstrated the best correlations with both biomarkers and various creatinine concentrations according to the IRIS. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. MDPI 2023-06-02 /pmc/articles/PMC10251965/ /pubmed/37889764 http://dx.doi.org/10.3390/ani13111853 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lapsina, Sandra Nagler, Nicole Müller, Simon F. Holtdirk, Annette Kottmann, Tanja Müller, Elisabeth von Luckner, Jennifer Schäfer, Ingo Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study |
title | Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study |
title_full | Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study |
title_fullStr | Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study |
title_full_unstemmed | Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study |
title_short | Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study |
title_sort | comparison of three different diagnostic assays for fibroblast growth factor-23 (fgf-23) measurements in cats: a pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251965/ https://www.ncbi.nlm.nih.gov/pubmed/37889764 http://dx.doi.org/10.3390/ani13111853 |
work_keys_str_mv | AT lapsinasandra comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT naglernicole comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT mullersimonf comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT holtdirkannette comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT kottmanntanja comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT mullerelisabeth comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT vonlucknerjennifer comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy AT schaferingo comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy |